Fibroblast Senescence As A Driver Of Pulmonary Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$845,611.00
Summary
Idiopathic pulmonary fibrosis (IPF) has no cure. Currently we think that IPF develops like normal wound healing, but the normal “braking” mechanisms in the myofibroblasts (the cells that produce the connective tissue) don’t work, such that too much connective tissue is produced and oxygen transfer to the blood is stopped. We have identified a protein we think stops, the myofibroblasts from dying. Reducing the activation of this protein should return the myofibroblasts function to normal.
Epithelial-Mesenchymal Cell Communication; Towards New Therapeutic Targets For Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$794,596.00
Summary
Fibrosis causes disability and death with millions of people affected each year. Current treatments are limited and there is a need to better understand the changes that drive fibrosis. In this study we will investigate how cells communicate to initiate and drive fibrosis. Using readily available drugs we will test new ways to alter cell communication to stop the disease and thus, develop a common and effective therapy that will change the future for people living with fibrosis.
In the asthmatic lung structural changes, such as increased deposition of proteins which form the scaffolding of the airways (the extracellular matrix proteins), and an increased mass of bronchial smooth muscle cells occur. Many of these critical structural changes are not reversed or prevented with current asthma therapy, thus we need to investigate, by using lung cells and tissues , why they happen and how we can prevent them.